Population pharmacokinetic model identifies an optimal fludarabine exposure for improved outcomes after CD19-directed CAR T cell therapy for aggressive B-NHL: Analysis from the Cell Therapy Consortium Meeting Abstract
| Authors: | Scordo, M.; Flynn, J. R.; Devlin, S. M.; Gonen, M.; Parascondola, A.; Tomas, A. A.; Shouval, R.; Brower, J.; Porter, D. L.; Schuster, S. J.; Bachanova, V.; Maakaron, J. E.; Maziarz, R. T.; Nastoupil, L. J.; McGuirk, J. P.; Oluwole, O. O.; Ip, A.; Leslie, L. A.; Bishop, M. R.; Riedell, P. A.; Perales, M. A. |
| Abstract Title: | Population pharmacokinetic model identifies an optimal fludarabine exposure for improved outcomes after CD19-directed CAR T cell therapy for aggressive B-NHL: Analysis from the Cell Therapy Consortium |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 1588 |
| End Page: | 1591 |
| Language: | English |
| ACCESSION: | WOS:000893223201243 |
| DOI: | 10.1182/blood-2022-164674 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work